NCT05618366 is a Phase 1 clinical trial of Venetoclax in Lymphoma, Non-Hodgkin, sponsored by Weill Medical College of Cornell University.

Who is sponsoring NCT05618366?

NCT05618366 is sponsored by Weill Medical College of Cornell University.

What drugs are being tested in NCT05618366?

Interventions in NCT05618366: Venetoclax, Tazemetostat.

What condition does NCT05618366 study?

NCT05618366 studies Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma.

Is NCT05618366 still recruiting?

NCT05618366 is currently terminated. Last updated 2 April 2026.

Last reviewed 2026-04-02 · How we verify

NCT05618366

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Terminated Phase 1 Last updated 2 April 2026

What this trial tests

Phase 1 trial testing Venetoclax in Lymphoma, Non-Hodgkin in 3 participants. Terminated before completion.

Timeline

7 June 2023

Primary endpoint
27 February 2026

27 February 2026

Quick facts

Lead sponsor	Weill Medical College of Cornell University
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	7 June 2023
Primary completion	27 February 2026
Estimated completion	27 February 2026
Sites	1 location across United States

Drugs / interventions tested

Venetoclax (venetoclax) — full drug profile →
Tazemetostat (tazemetostat) — full drug profile →

Conditions studied

Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →
Diffuse Large B Cell Lymphoma — all drugs for Diffuse Large B Cell Lymphoma →
Follicular Lymphoma — all drugs for Follicular Lymphoma →

Sponsor

Weill Medical College of Cornell University

Who can join

18 and older, any sex, with Lymphoma, Non-Hodgkin or Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main questions that this trial aims to answer are what is the best dose of venetoclax to give with tazemetostat to people with R/R NHL; what types of side effects do people with R/R NHL get when taking venetoclax with tazemetostat; and what effects does this combination have on R/R NHL. Participants will need to take pills by mouth every day and regularly come to the clinic for blood work and imagining to monitor side effects and cancer progression. Participants may receive study drugs for up to 24 months.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives.
Caridà G, Martino EA, Bruzzese A, Caracciolo D, et al · · 2025 · cited 3× · PMID 39971627 · DOI 10.1111/ejh.14401
Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine.
Wang Z, Feng S, Yao X, Zhao R, et al · · 2025 · cited 2× · PMID 40703518 · DOI 10.3389/fimmu.2025.1620895
BMP-ACVR1 Axis is Critical for Efficacy of PRC2 Inhibitors in B-Cell Lymphoma.
Liu D, Li Z, Tan D, An Y, et al · · 2024 · cited 2× · PMID 38229201 · DOI 10.1002/advs.202306499
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6).
Witte HM, Riedl J, Künstner A, Fähnrich A, et al · · 2023 · cited 2× · PMID 37488307 · DOI 10.1007/s11523-023-00983-5
The role of <i>EZH2</i> dysregulation in the pathogenesis of B-cell lymphomas and its implications as a target therapy.
Candelaria M. · · 2026 · PMID 42211521 · DOI 10.3389/fonc.2026.1843273
2026 Update on the Management of Diffuse Large B-Cell Lymphoma.
Chong EA, Tomasulo EB, Barta SK. · · 2026 · PMID 41654318 · DOI 10.1002/ajh.70229

Verify or expand the search:

Other trials of Venetoclax

Trials testing the same drug.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07511062 — Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML · Phase 1 · not yet recruiting

Other recruiting trials for Lymphoma, Non-Hodgkin

Currently open trials in the same condition.

NCT07308132 — A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · Phase 1 · recruiting
NCT06923397 — Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemother · NA · recruiting
NCT06660563 — A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell No · Phase 1 · active not recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT06470438 — A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma · Phase 1 · active not recruiting

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2 · NA · not yet recruiting
NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1 · NA · not yet recruiting
NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression · NA · not yet recruiting
NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3 · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05618366 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05618366.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing